Novartis, in partnership with Dawn Health, introduced Cora BC, a digital solution designed to support individuals with breast cancer on their treatment journey.

The app comprises tools that offer health tracking, personalised content, and medication reminders to help patients manage their condition.

Cora BC claims to enable patients to complete their regular health check-ins and “visualise” their progress via intuitive graphs.

The app's features are tailored to make patients build their habits and routines, which are crucial for adhering to multi-year treatments, Dawn Health noted.

It also offers educational resources, actionable advice and diary functions to help patients prepare for healthcare consultations.

Anticipated to be launched initially in Germany, the app will also be available in the UK, Australia, Canada, and other markets soon.

Dawn Health CEO Alexander Mandix Hansen said: “Cora BC is more than a tool—it’s a step toward better care.

“By partnering with Novartis, we’re ensuring breast cancer patients have access to the resources and support they need to feel seen, heard, and empowered to achieve the best possible outcomes. This app reflects our shared commitment to innovation and patient-centric care.”

The launch of Cora BC builds on the previous partnership between the two companies on developing Ekiva MS and Ekiva PNH for multiple sclerosis and paroxysmal nocturnal haemoglobinuria patients, respectively.

Ekiva PNH was introduced by the companies in April last year.

Dawn Health focuses on developing software as a medical device (SaMD) and digital therapeutics (DTx).

In collaboration with pharmaceutical companies, the company works to advance the creation and implementation of digital tools for patient care and management of chronic conditions.